UPCC 07419: A Phase 1b/2a Multicenter Open-Label Dose Escalation Study to Determine the Maximum Tolerated Dose Assess the Safety Tolerability Pharmacokinetics and Efficacy Of Cc-220 Monotherapy and In Combination With Other Treatments In Subjects With Relapsed and Refractory Multiple Myeloma

Recruiting
99 years or below
All
Phase 2
1 Location

Brief description of study

The purpose of this study is to test the safety of an experimental drug CC-220, alone and in combination with other treatments. The study is also designed to define the appropriate dose for further testing of the study drug and these experimental combinations.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 09 Apr 2021. Study ID: 832983

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.